5AM Venture Management, LLC
5AM Venture Management, LLC reported 16 US-listed holdings worth $287.9 million in its 13F for the quarter ended 30 June 2026, filed 14 August 2026. Its largest: Maplight Therapeutics Inc. (11.8%), Tyra Biosciences Inc. (11.4%) and Entrada Therapeutics Inc. (10.4%). Against the quarter before, it opened 0 positions, added to 0, trimmed 1 and sold out of 4.
The 14 largest of its 16 positions, each sized by its share of the reported holdings, coloured by the change in shares against Q1 2026.
What the fund reported holding at each quarter's end; hover a bar for the number of positions
What its reported holdings returned
Held through each quarter, the holdings it reported returned +52.7% over the 7 quarters to 30 June 2026, against +30.2% for the S&P 500.
Not the fund's own return: each 13F's holdings are kept unchanged until the next one, so trades inside a quarter, dividends, cash and fees are left out. A rough guide to how its picks have done over time.
What it did on the quarter
Its positions against its 13F for the quarter to 31 March 2026; a change under 0.1% of a position counts as held
Trimmed 1
- Surrozen Inc. SRZN-116,250 shares · -30%
Sold out of 4
- Erasca Inc. ERAS$56.4 million last quarter
- Centessa Pharmaceuticals PLC CNTA$23.1 million last quarter
- GH Research PLC GHRS$8.1 million last quarter
- Rallybio Corp. Com RLYB$2.6 million last quarter
What it holds
| Company | Shares | Value | Of its book | Change in shares |
|---|---|---|---|---|
| Maplight Therapeutics Inc. MPLT | 950.0K | $34.0 million | 11.83% | no change |
| Tyra Biosciences Inc. TYRA | 1.0M | $32.9 million | 11.42% | no change |
| Entrada Therapeutics Inc. TRDA | 4.1M | $29.9 million | 10.37% | no change |
| Pharvaris N V PHVS | 797.6K | $27.6 million | 9.58% | no change |
| CAMP4 Therapeutics Corp. CAMP | 5.9M | $25.6 million | 8.91% | no change |
| Artiva Biotherapeutics Inc. ARTV | 2.4M | $22.8 million | 7.93% | no change |
| Tectonic Therapeutic Inc. TECX | 606.7K | $20.9 million | 7.24% | no change |
| Zentalis Pharmaceuticals Inc. ZNTL | 3.9M | $19.1 million | 6.65% | no change |
| Celldex Therapeutics Inc. CLDX | 497.3K | $18.5 million | 6.43% | no change |
| Eyepoint Pharmaceuticals Inc. EYPT | 1.1M | $15.0 million | 5.22% | no change |
| Biohaven Ltd BHVN | 739.0K | $11.0 million | 3.82% | no change |
| Surrozen Inc. SRZN | 271.2K | $7.0 million | 2.44% | -116.2K |
| Skye Bioscience Inc. SKYE | 9.7M | $6.7 million | 2.33% | no change |
| Alx Oncology Holdings Inc. ALXO | 3.1M | $6.3 million | 2.20% | no change |
| Protara Therapeutics Inc. TARA | 1.4M | $5.2 million | 1.82% | no change |
| Silence Therapeutics PLC SLN | 476.2K | $5.2 million | 1.82% | no change |